Results 261 to 270 of about 754,612 (422)

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease [PDF]

, 2000
Hirokazu Taniguchi, Shigeki Katoh, Jun‐ichi Kadota, Y Matsubara, Kiyoyasu Fukushima, Hiroshi Mukae, Shigeru Matsukura, S Kohno   +7 more
openalex   +1 more source

The use of mechanical ventilation in interstitial lung disease. [PDF]

Breathe (Sheff)
Nolan TJ, Dwyer I, Geoghegan P.
europepmc   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

Pulmonary Lymphangitic Sarcomatosis from Cutaneous Angiosarcoma: an Unusual Presentation of Diffuse Interstitial Lung Disease [PDF]

, 2000
Chi‐Ting Liau
openalex   +1 more source

Genomic classifier: biomarker for progression in interstitial lung disease. [PDF]

ERJ Open Res
Parrish R, Kheir F.
europepmc   +1 more source

Increased calcification by erythrophagocytosis in aortic valvular interstitial cells

ESC Heart Failure, Volume 12, Issue 2, Page 1469-1473, April 2025.
Abstract Background Calcific aortic valve disease (CAVD) progresses over time to severe aortic stenosis and eventually heart failure. Recent evidence indicates that intraleaflet haemorrhage (ILH) strongly promotes CAVD progression. However, it remains poorly understood how it mechanistically contributes to valvular calcification.
Zihan Qin, Magnus Bäck, Anders Franco‐Cereceda, Sven‐Christian Pawelzik   +3 more
wiley   +1 more source

Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis Responding to Intravenous Cyclophosphamide Pulse Therapy.

, 1997
Tadashi Shinohara, Toshihiko Hidaka, Yasunori Matsuki, Toshiaki Ishizuka, Mitsuyo Takamizawa, Makoto Kawakami, Hideki Kikuma, Kimihiro Suzuki, Haruo Nakamura   +8 more
openalex   +2 more sources

Progression of interstitial lung disease after the Envisia Genomic Classifier. [PDF]

ERJ Open Res
Chung A, Oh A, Durant C, Watson R, Channick J, Fishbein G, Pourzand L, Kim S, Ronaghi R, Oh S, Kim G, Weigt SS.   +11 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source